ABSTRACT. CD9 and CD63 belong to a tetramembrane-spanning glycoprotein family called tetraspanin, and are involved in a wide variety of cellular processes, but the structure-function relationship of this family of proteins has yet to be clarified. CD9 associates with diphtheria toxin receptor (DTR), which is identical to the membraneanchored form of heparin-binding EGF-like growth factor (proHB-EGF). CD9 upregulates the diphtheria toxin (DT) binding activity of DTR/proHB-EGF, while CD63 does not upregulate the DT binding activity in spite of the fact that this protein also associates with DTR/proHB-EGF on the cell surface. CD9 molecules localize on the cell surface, while those of CD63 localize predominantly at lysosomes and intracellular compartments. We made CD9/ CD63 chimeric molecules and then studied their intracellular localization and upregulation activities. The C-terminal regions of CD63, which includes the lysosome sorting motif, showed a strong inhibitory effect on the expression of the chimeric proteins at the cell surface, while mutants lacking the lysosome sorting motif delivered more efficiently on the cell surface, indicating that the lysosome sorting motif contributes to the inhibitory effect of the C-terminal region. However, the N-terminal half of this family of proteins containing the 1st to 3rd transmembrane domains also seems to influence the cell surface expression. For the upregulation of DT binding activity the large extracellular loop (EC2) of CD9 was essential, while the remaining regions influenced the upregulation activity by changing the efficiency of cell surface expression. From these results we discussed the structure-function relationship of this family of proteins.
and large extracellular loops (EC1 and EC2). EC2, located between TM3 and TM4, contains the conserved cysteine residues. Although the general function of this family of proteins has not been elucidated, it has been described in a wide variety of animal cells including C. elegans and Drosophila, as well as in vertebrate. Because of the family member's tendencies to form complexes with a variety of membrane proteins, they are thought to be 'adapters for membrane proteins', or 'molecular facilitators', that mediate the formation of large molecular complexes allowing them to function more efficiently (Maecker et al., 1997; Hemler, 1998) .
CD9, one of the most characterized members of the tetraspanins, was initially reported to be expressed in preB cells and platelets (Boucheix et al., 1983; Kersey et al., 1981) , but further studies have revealed that it is expressed in a wide variety of hematopoietic and non-hematopoietic cells (Boucheix et al., 1991; Lanza et al., 1991; Iwamoto et al., 1991; Mitamura, et al., 1992) . Increasing evidence suggests that this protein is involved in a variety of functions, such as cell signaling (Tai et al., 1996; Griffith et al., 1991) , cell growth , cell motility (Shaw et al., 1995; Schmidt et al., 1996) , cell adhesion Anton et al., 1995; Masellis-Smith and Shaw, 1994) , tumor cell metastasis (Ikeyama et al., 1993; Miyake et al., 1991; Si and Hersey, 1993) , muscle cell formation (Tachibana and Hemler, 1999) , development and maintenance of the neural system (Kaprielian et al., 1995; Tole and Patterson, 1993; Nakamura et al., 1996; Kagawa et al., 1997) , sperm-egg fusion (Miyado et al., 2000; Le Naour et al., 2000; Kaji et al., 2000) and viral infections (Loffler et al., 1997; Schmid et al., 2000) . CD9 forms complexes with a number of membrane proteins which include integrin =3>1 (Nakamura et al., 1995) , =6>1 (Berditchevski et al., 1996; Hadjiargyrou et al., 1996) , the neural adhesion molecule L1 (Schmidt et al., 1996) , CD46 (Lozahic et al., 2000) , the membrane-anchored form of heparin-binding EGF-like growth factor (proHB-EGF) (Iwamoto et al., 1994) and other members of the tetraspanins .
CD63, also called ME491 or lamp3 (Hotta et al., 1988; Fukuda, 1991) , is another member of the tetraspanins, and is also known to associate with integrin =3>1, integrin =6>1 or other tetraspanins (Berditchevski et al., 1996) . A fraction of this protein exists on the cell surface, but this protein localizes predominantly at intracellular compartments including late endodome/lysosome (Griffiths, 1996) , azurophilic granules of neutrophils (Cieutat et al., 1998 ), =-granules of platelets (Heijnen et al., 1998) , Weibel-Palade bodies of endothelial cells (Vischer and Wagner, 1993) and MHC class II compartment (Calafat et al., 1994) . CD63 is delivered from secretory granules to the cell surface by various stimuli-induced mechanisms, and cycles between endocytic and secretory compartments .
Although increasing evidence suggests that the tetraspanins are involved in a wide variety of cellular processes during embryonal development and the maintenance of mature individuals, the general molecular functions of this family and the structural requirements for these functions remain to be clarified. Since this family of proteins, which includes CD9 and CD63, has no known domain structures within the molecules, it is difficult to anticipate a structure-function relationship from their primary sequences. One particular function of CD9 is its co-receptor activity for the diphtheria toxin receptor (DTR). CD9, originally reported as DRAP27 (Iwamoto et al., 1991) , associates with DTR (Iwamoto et al., 1994) and upregulates the diphtheria toxin (DT) binding activity of DTR (Mitamura et al., 1992; Iwamoto et al., 1994) . DTR and proHB-EGF are identical molecules, thus CD9 upregulates the juxtacrine mitogenic activity of DTR/ proHB-EGF . Although CD63 also associates with DTR/proHB-EGF on the cell surface, this protein does not enhance the DT-binding activity, nor does it enhance the juxtacrine mitogenic activity, but rather elucidate it decreases the upregulation effect of CD9 . In order to the structure-function relationship of these proteins, we made serial chimeric molecules between CD9 and CD63. By taking advantage of the differences between CD9 and CD63, we studied the regions necessary for cellular localization and upregulation for DT binding.
Materials and Methods

Antibodies
Mouse anti-human CD9 mAbs (monoclonal antibody) TP82 and BU16 were purchased from Nichirei (Tokyo, Japan) and Biogenesis (Poole, England, UK), respectively. Mouse anti-human CD63 (CLB-gran12) mAb and rabbit anti-rat cathepsin D antibody were obtained from Immunotek (Merseille Cedex, France) and Wako (Osaka, Japan), respectively. Cy3-conjugated goat anti-mouse IgG and HRP-conjugated anti-mouse IgG were purchased from Chemicon (Temecula, CA, USA). Alexa Fluor 568 goat anti-mouse IgG and Alexa Fluor 488 goat anti-rabbit IgG were from Molecular Probes (Eugene, OR, USA). Goat anti-mouse IgG was purchased from Cappel (West Chester, PA, USA).
Plasmid constructions
The CD9/CD63 chimeric molecules constructed in this study are shown in Fig. 1 . Plasmids encoding monkey CD9 were used as described previously (Mitamura et al. 1992) . cDNA encoding human CD63 (Hotta et al., 1988) were kindly provided by Dr. H. Hotta (Kobe University). These cDNAs were inserted into the HindIII/ XbaI site in the expression vector, pRc/CMV (Invitrogen, Groningen, The Netherlands). CD9/CD63 chimeras were constructed as follows: NdeI and NarI sites were introduced into CD9 cDNA as described previously and the AflII site by substituting 639 C to A. The resulting plasmid containing NdeI, NarI and AflII sites, referred to as yCD9, has no amino acid substitutions. NdeI and NarI sites were introduced into CD63 cDNA by site-directed mutagenesis, in which the coding sequence of CD63 cDNA were substituted from 306 TGC to ATG and from 620 CTGCA to GCGCC, respectively. These substitutions resulted in amino acid alterations from 102 Ala to Cys and 207 Ala to Gly. ME6, ME8, DR18 and DR20 were constructed by exchanging the coding sequence using the NdeI and NarI sites. DR14 was constructed by using the AflII site. ME6(DGY), CD63(DGY), ME6(AA) and CD63(AA) were synthesized by polymerase chain reaction using primers containing the corresponding mutations. All the constructed CD9/CD63 chimeras were inserted in pRc/CMV.
SDS-PAGE and immunoblot
Cells were lysed with 60 mM octyl-b-D-glucoside in lysis buffer (30mM N-2-hydoroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), pH 7.0, 0.3 M NaCl, 1 mM EDTA, 1 mM PMSF, 20mg/ ml Antipain, 10 mg/ml chymostatin), after which the lysates were centrifuged for 20 min at 40,000´g. The supernatants were then boiled for 5 min in SDS-PAGE sample buffer without reducing agents, subjected to SDS-PAGE (12% gel) and electrotransferred to an Immobilon membrane (Millipore Ltd.). The membrane was blocked with TBS (20 mM Tris-HCl, 100 mM NaCl, pH 7.5) containing 3% skim milk at room temperature for 60 min, and then incubated at room temperature with the first antibody at a concentration of 2 mg/ml in TBS2 (20 mM Tris-HCl, 300 mM NaCl, pH 7.5) containing 1% skim milk. After washing with TTBS (TBS containing 0.05% Tween 20), the membranes were incubated with HRP-conjugated anti-mouse IgG (Chemicon) at a concentration of 2 mg/ml, washed 3 times with TTBS, and analyzed with an ECLWestern blotting detection reagents (Amersham Pharmacia Bioteck, Buckinghamshire, England ).
Cell culture and transfection
Rat 3Y1 cells, mouse L cells and LC cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FCS, penicillin G (100 unit/ml ) and streptomycin (100 mg/ml ). Transfections of plasmids into L cells and LC cells were carried out by the calcium phosphate method (Chen and Okayama, 1988) . 3Y1 cells were transfected by electropolation using a Gene Pulser II (BioRad Laboratories, Philadelphia, PA, USA).
DT binding assay
Binding of 125 I-labeled DT to cells was measured as described previously (Mitamura et al., 1997) . Nonspecific binding of 125 I-DT was assessed in the presence of a 100-fold excess of unlabeled DT. Specific binding was determined by subtracting the nonspecific binding from the total binding obtained with 125 I-DT alone. The amount of DT bound to the cells was then calculated from the value of the specific binding of DT.
Antibody binding assay
Purified goat anti-mouse IgG was labeled with Na 125 I using Iodogen pre-coated tube (Pierce, Rockford, IL, USA ). The labeled antibody had a specific activity of about 5-6´10 3 cpm/ng. 3Y1 cells, L cells or LC cells were plated on 24-well plates at 1´10 5 cells/ well and incubated for 16 hr at 37°C. The cells were incubated with 1 mg/ml of anti-CD9 (TP82) or anti-CD63 mAb in binding medium (MEM containing nonessential amino acids, 10% FCS, 20 mM HEPES, pH 7.2 and 3 mM NaN3) for 2 hr at 4°C. After washing three times with PBS(+) containing 1% FCS, cells were incubated with 1 mg/ml of 125 I-labeled anti-mouse IgG for 2 hr at 4°C. Cells were then washed with PBS(+) containing 1% FCS three times, lysed with 0.1N-NaOH, and cell-associated radioactivity was measured by a g-counter.
Fluorescent microscopic analysis
Twenty-four hours after transfection, 3Y1 cells were replated on coverslips and the culture continued for 24 hr. For staining under non-permeabilized conditions, cells were stained with anti-CD9 (TP82) or anti-CD63 mAb in staining buffer (PBS(+) containing 1% skim milk) for 2 hr at 4°C. After again washing three times with PBS(+), cells were fixed with 3.7% (w/v) formaldehyde in PBS(+) for 30 min at 4°C. After washing three times with PBS(+), cells were incubated with Cy3-conjugated anti-mouse IgG at room temperature for 30 min. For staining under permeabilized conditions, cells were fixed with 3.7% (w/v) formaldehyde in PBS(+) for 30 min at 4°C, washed with PBS(+) three times, and permeabilized with 0.1% Triton X-100 for 3 minutes. The cells were then incubated with blocking solution (10mM Tris/HCl, pH8.0 containing 0.1 M glycine) for 30 min, followed by incubation with 1% skim milk in PBS(+) for 30 min. Cells were stained with rabbit anti-rat cathepsin D antibody and either anti-CD9 (TP82) or anti-CD63 mAb for 1 hour at room temperature, followed by incubation with Alexa Fluor 488-conjugated goat anti-rabbit IgG and Cy3-conjugated goat anti-mouse IgG antibody for 30 minutes at room temperature. Immunofluoresence was observed using an figure. yCD9, which introduced NdeI(Nd), NarI(Na) and AflII(Af) sites within the coding sequence of CD9, has no amino acids substitution from the original CD9. CD63 has a lysosomal sorting motif (Gly-Tyr) at the Cterminal cytoplasmic domain. ME6(AA) and CD63(AA) are mutants of ME6 and CD63 whose Gly-Tyr residues were substituted to Ala-Ala. ME6(DGY) and CD63(DGY) are deletion mutants lacking these two amino acid residues. N-linked glycosylation sites in the EC2 of CD63 are also shown.
OLYMPUS BX50 microscope (Olympus, Tokyo, Japan ) and images were captured with a FISH imager system (Carl Zeiss, Jena, Germany) and manipulated with Adobe Photoshop 4.0 J software.
Results
Construction and expression of chimeric molecules Fig. 1 shows the CD9/CD63 chimeric molecules studied in this study. The open and shaded boxes represent the regions of CD9 and CD63, respectively. The putative transmembrane regions (TM1-TM4) and the extracellular loops (EC1 and EC2) are shown in the bars at the top of the figure. yCD9, which introduced NdeI, NarI and AflII sites within the coding sequence of CD9, has no amino acid substitutions from the original CD9. CD63 has a lysosomal sorting motif (Gly-Tyr) at the C-terminal cytoplasmic domain (Metzelaar et al., 1991; Harter and Mellman, 1992) . ME6(AA) and CD63(AA) are mutants of ME6 and CD63 whose Gly-Tyr residues were substituted to Ala-Ala. ME6(DGY) and CD63(DGY) are deletion mutants lacking these two amino acid residues.
Rat 3Y1 cells were transiently transfected with plasmids encoding the chimeric molecules, wild type CD9 or wild type CD63. Fig. 2 demonstrates the chimeric molecules expressed in 3Y1 cells by western blotting using anti-CD9 or anti-CD63 mAb. Antibodies used here recognize EC2 of each protein. The EC2 of CD63 is highly glycosylated, therefore CD63 gave smear bands ranging from 30 to 55 kDa, while CD9 migrates in a single band at about 27 kDa. Consistent with the location of glycosylation sites within EC2, CD63(DGY), CD63(AA) and DR20, which have the EC2 of CD63, gave smear bands similar to CD63, while DR14, DR18, ME6 and ME8 gave single bands with expected sizes.
Immunofluorescent localization of chimeric molecules
When plasmids encoding CD9 were transiently transfected into 3Y1 cells and the localization of CD9 was studied by immunofluorescent staining under non-permeabilized conditions, a strong fluorescence of CD9 was observed on the cell surface (Fig. 3b) . No fluorescence was observed in cells transfected with the vector only (Fig. 3a) . CD9 localized in cell-cell contact sites, microvilli-like projections from the free cell surface and dot-like structures over the cell surface, as has been reported in other cell lines (Nakamura et al., 1995) . However, the expression of CD63 on the cell surface was hardly observed by immunofluoresence using anti-CD63 mAb in cells transfected with plasmids encoding CD63 (Fig. 3i) . When immunostaining was performed for permeabilized cells, anti-CD63 mAb stained intracellular vesicular structures (see Fig. 4 ), indicating that CD63 was expressed in 3Y1 cells and mainly localized inside cells. Immunofluorescent staining of nonpermeabilized cells was also performed for CD9/CD63 chimeras using anti-CD9 or anti-CD63 mAb. Fluorescence of ME6 was not observed on the cell surface (Fig. 3c) . A faint fluorescence on the cell surface was observed for DR14 (data not shown) and DR18 (Fig. 3d) . A moderate fluorescence was observed for ME8 (Fig. 3e) . Strong cellsurface staining was observed for DR20, whose staining pattern was similar to CD9 (Fig. 3j) . These results indicate that the surface expressions of the chimeric molecules are greatly influenced by the C-terminal region of CD63.
In order to determine the effect of the GY motif of CD63 on the cell surface localization of chimeric molecules, two kinds of mutants lacking the GY residues were constructed for CD63 and for ME6 (see Fig.1 ). In contrast with CD63, CD63(,GY) (Fig. 3k) and CD63(AA) (Fig. 3l) , stained with anti-CD63 mAb, showed apparent fluorescence indicating the cell surface expression of these mutant proteins. Expres- Fig. 2 . Expression of CD9/CD63 chimeras in 3Y1 cells. 3Y1 cells were transfected with plasmids encoding CD9, CD63 or CD9/CD63 chimeras. After incubation for 48 h, cell lysates were analyzed by SDS-PAGE, followed by western blotting using anti-CD9(TP82) or anti-CD63 mAb, and a HRP-conjugated second antibody. Bars on the left margin show molecular weight markers in kilodaltons. Fig. 3 . Immunofluorescent staining of 3Y1 cells transfected with CD9/CD63 chimeras under non-permeabilized conditions. 3Y1 cells were transfected with plasmids encoding CD9, CD63, indicated CD9/CD63 chimeras or vector only (MOCK). After 48 hr of transfection, cells were stained with anti-CD9 mAb(TP82) (a-g), or anti-CD63 mAb (h-l), and then the CY3-conjugated second antibody as described in Materials and Methods. Phase contrast views of same fields are shown in (a'-l'). sion on the cell surface was also observed for ME6(,GY) ( Fig. 3f) and ME6(AA) (Fig. 3g) . No particular differences of the staining patterns between ME6(,GY) and ME6(AA), or CD63(,GY) and CD63(AA) was observed. These results indicate that the GY motif caused reduced expression of chimeric molecules on the cell surface.
Immunofluorescent staining was also performed in permeabilized cells, and CD9 and CD63 showed quite different patterns. CD9 showed bright dot-like stains at the perinuclear space with a lesser scatter staining pattern all over the cells (Fig. 4a) , which partly resembled the staining pattern of CD9 in non-permeabilized cells, probably because CD9 exists mainly at the cell surface. CD63 localized in vesicular structures at the perinuclear space (Fig. 4d) . Immunofluorescence of cathepsin D, a marker of lysosomes (Fig. 4d' ), overlapped well with that of CD63 (Fig. 4d'' ), indicating that exogenously expressed CD63 mainly localized in lysosomes. DR20 (Fig. 4e) , CD63(,GY) ( Fig. 4f) and CD63(AA) (data not shown) showed vesicular staining patterns similar to CD63, overlapped with cathepsin D, indicating that these molecules localize not only at the cell surface but also in lysosomes. Surprisingly, although ME6 and ME8 showed vesicular staining patterns, these did not overlap with those of cathepsin D, giving rise to the possibility that these molecules may not accumulate in lysosomes (Fig.  4b, 4c ).
Cell surface expression of chimeric molecules
Immunofluorescent staining revealed that the chimeric molecules containing the C-terminal region of CD63 including the GY motif were arrested in expressing their proteins on the cell surface. In order to determine the amounts of each chimeric molecule on the cell surface in a more quantitative manner, an antibody-binding assay was performed in which the amounts of the chimeric molecules on the cell surface were measured by the binding of either anti-CD9 or anti-CD63 mAb and the 125 I-labelled second antibody. Although it is difficult to determine the absolute amounts of chimeric molecules on the cell surface by such an indirect method, it is possible to determine the relative amounts among the chimeric molecules with the same EC2 domains. Results are shown in Fig. 5 . Among CD9 and chimeric molecules consntaining the EC2 of CD9, CD9 was the most abundantly expressed on the cell surface, whereas ME6 had the minimum expression. Consistent with the immunofluorescent staining, ME6(AA) and ME6(,GY) were more highly expressed on the cell surface than ME6. Among CD63 and chimeric molecules containing the EC2 of CD63, DR20 showed the highest amounts. Binding of anti-CD63 mAb was scarcely detected in intact cells transfected with CD63. CD63(,GY) and CD63(AA) showed a moderate binding of anti-CD63 mAb, confirming that deletion of the GY motif of CD63 leads to their localization toward the cell surface. However, the amounts of CD63(,GY) and CD63(AA) on the cell surface were much lower than that of DR20. Similarly, the amount of CD9 on the cell surface was much higher than ME6(AA), ME6(,GY) or ME8. Thus, in addition to the C-terminal region, some other regions may have some effect on localization.
Upregulation of DT binding by the chimeric molecules
We tested the upregulation activity of each chimeric molecule for DT binding. As described previously (Mitamura et al., 1995) , mouse L cells were transiently transfected with plasmids encoding DTR/proHB-EGF and one of the CD9/ CD63 chimeras, and a binding assay of 125 I-labelled DT was performed (Fig. 6A ). L cells have no DT binding activity, because L cells express mouse proHB-EGF but mouse pro-HB-EGF does not bind DT (Mitamura et al., 1995) . DT bound to cells expressing DTR/proHB-EGF alone, but the amount was low compared with cells expressing DTR and CD9. Co-transfection of CD9 with DTR/proHB-EGF resulted in a marked upregulation of DT binding. As shown in Fig. 6A , the chimeras containing the EC2 of CD9 upregulated the binding activity for DT, though the upregulation levels were much less than that of CD9. However, chimeric molecules containing the EC2 of CD63 did not show any upregulation activity. These results are consistent with the results of CD9/CD81 chimeras , and indicates that the EC2 of CD9 is required for upregulation. To determine cell surface expression levels of CD9/CD63 chimeric molecules in L cells, antibody binding assay was simultaneously performed (Fig. 6B ). ME6 and DR14 showed both the minimum cell surface expressions and the minimum upregulation activities compared with other chimeras containing the EC2 of CD9. ME6(AA) and ME6(,GY) were expressed on the cell surface more than ME6, and showed higher upregulation activity. CD9 showed both the maximum surface expression and the maximum upregulation activity. Thus, the relative amounts of chimeric molecules on the cell surface were well correlated with the upregulation activity unless the chimeric molecules had the EC2 of CD9. These results revealed that cell surface expression of chimeric molecules is required for the upregulation of DT binding activity.
Inhibition of the upregulation effect of CD9 with the chimeric molecule
Previous studies have shown that the overexpression of other tetraspanins, including CD63, results in the partial inhibition of the upregulation effect of CD9 . We examined here whether any CD9/CD63 chimeric molecules showed such inhibitory effect for CD9-induced upregulation (Fig. 7) . For this study LC cells, that is L cells stably expressing CD9, were transiently transfected with both DTR/proHB-EGF and one of the chimeric molecules, and then followed by DT binding assay. Since LC cells constitutively express a fairly large amount of CD9, transfection of plasmids encoding CD9 resulted in only a slight upregulation. Although most chimeric molecules in LC cells did not particularly inhibit DT binding, DR20 markedly inhibited it, giving rise to the possibility that this molecule may be used as a dominant negative inhibitor of CD9 or DTR/proHB-EGF.
Discussion
Both immunofluorescent staining of non-permeabilized cells and the antibody binding assay indicated that chimeras possessing the C-terminal region of CD63 scarcely expressed on the cell surface, as did CD63, while chimeras possessing the C-terminal region of CD9 expressed on the cell surface. These results were observed both in 3Y1 cells and L cells. The deletion or substitution of the GY motif of the C-terminal region of CD63, a lysosome sorting signal, resulted in increased expression on the cell surface. These results clearly indicated that the GY motif within the C-terminal region caused major reductions of the amounts of chi- meric molecules on the cell surface. These reduced expressions on the cell surface are most likely due to the results of the preferential sorting to lysosomes. However, the present results cannot exclude other possibilities, such as the enhanced recycling of proteins from the cell surface into intracellular vesicles after sorting on the cell surface.
Although ME8, ME6(AA) and ME6(,GY) are lacking the GY motif in the C-terminus, the amounts of these proteins on the cell surface were lower than that of CD9 as shown by both immunofluorescent staining and antibody binding assay. Similarly, DR20 expressed much more on the cell surface than CD63(,GY) or CD63(AA). Thus, not only the GY motif but also other regions of CD63, most probably the N-terminal half of CD63 containing TM1-TM3, influence the amounts of chimeric molecules on the cell surface.
In permeabilized cells the fluorescence of CD63(,GY) or CD63(AA) overlapped well with the fluorescence of cathepsin D, as with that of CD63, indicating that these chimeric molecules localize at lysosomes. These results may suggest that not only the GY motif but also some other region of CD63 contributes to the lysosome sorting. Fluorescence of ME6 and ME8, however, did not appear to overlap with cathepsin D. Although ME6 possesses transmembrane domains of CD63, it seems to be sorted to compartments other than lysosomes. The EC2 of CD63 might have some function for the correct sorting to lysosomes, and therefore ME6 and ME8, lacking the EC2 of CD63, could be mis-sorted to other compartments. Alternatively, these chimeras might be sorted to lysosomes and other intracellular compartments just as CD63 itself is sorted, but that ME6 and ME8 could be degraded in lysosomes due to the EC2 of CD9. Further studies are needed to clarify this point.
DT binding assay indicated that chimeras possessing the EC2 of CD9 upregulated DT binding activity to a greater or lesser extent, while chimeras possessing the EC2 of CD63 failed to upregulate. Thus, the EC2 of CD9 is required for upregulation of DT binding. These results are quite consistent with an earlier study . Moreover, the present results showed that the upregulation activity correlates well with the amounts of chimeric molecules on the cell surface. Thus, it is concluded that the expression of chimeras on the cell surface is also required for upregulation, and that some other regions of EC2 also contribute to the upregulation activity of CD9.
The inhibitory effect of DR20 on DT binding in LC cells should be noted. DR20 might be used as an inhibitor of DTR/proHB-EGF. In contrast, ME6, an opposite type to DR20, did not show any inhibitory effect for DT binding. Although it is not clear why DR20 shows an inhibitory effect on DT binding, the following possibilities are conceivable: 1) that DR20 serves as an inhibitor of CD9 and thus inhibits the upregulation activity of CD9, 2) that DR20 associates directly to DTR/proHB-EGF and inhibits the DT binding activity as an inhibitor of DTR/proHB-EGF, or 3) that expression of DR20 induces mis-sorting of DTR/pro-HB-EGF and thus causes a reduction of functional DTR/ proHB-EGF molecules. Further studies on the inhibitory effects of DR20 would better clarify the structure-function relationship of the tetraspanins, and could provide successful constructions of dominant negative inhibitors of this family of molecules.
In conclusion, both EC2 and the remaining domains of CD9 contribute in different ways to the upregulation activity for DT binding. The EC2 of CD9 are primarily essential for upregulation and would not be substituted. The remaining regions containing transmembrane domains would provide cell surface localization of CD9 and are thus also required for upregulation. It has recently been reported that CD151, another member of the tetraspanins, binds to integrin =3>1 by the interaction of the EC2 of CD151 with the extracellular domain of the integrin (Yauch, et al., 2000) Thus the EC2 of tetraspanins may generally serve for the specific interaction of associated proteins, and the remaining regions, containing the transmembrane domains and the N-and C-terminal regions, may serve to determine the intracellular localization of this family of proteins.
